Literature DB >> 11012762

Feline leukaemia virus: protective immunity is mediated by virus-specific cytotoxic T lymphocytes.

J N Flynn1, L Hanlon, O Jarrett.   

Abstract

Feline leukaemia virus (FeLV) nucleic acid vaccination of domestic cats affords protection against viraemia and the development of latency without inducing antiviral antibodies.1 To determine the contribution of cell-mediated immunity to the control of virus replication and clearance from the host, FeLV-specific cytotoxic T lymphocyte (CTL) responses were compared in vaccine-protected, transiently viraemic, and persistently viraemic cats. Vaccinal immunity was associated with the detection of higher levels of virus-specific effector CTL in the peripheral blood and lymphoid organs to FeLV Gag/Pro and Env antigens than those observed in unvaccinated control, persistently viraemic cats (P<0.001). Likewise, higher levels of virus-specific CTLs were also observed in transiently viraemic cats which recovered following exposure to FeLV. In cats that controlled their infection, recognition of Gag/Pro antigens was significantly higher than the recognition of Env antigens. This is the first report highlighting the very significant role that virus-specific CTL have in determining the outcome of FeLV infection in either vaccinated cats or cats recovering naturally from FeLV exposure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012762      PMCID: PMC2327065          DOI: 10.1046/j.1365-2567.2000.00089.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  32 in total

1.  Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus.

Authors:  U Dittmer; B Race; K J Hasenkrug
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Development of a whole killed feline leukemia virus vaccine.

Authors:  S M York; C J York
Journal:  J Am Vet Med Assoc       Date:  1991-11-15       Impact factor: 1.936

3.  Protection of kittens from feline leukaemia virus infection by maternally-derived antibody.

Authors:  O Jarrett; P H Russell; M F Stewart
Journal:  Vet Rec       Date:  1977-10-08       Impact factor: 2.695

4.  High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals.

Authors:  F M Gotch; D F Nixon; N Alp; A J McMichael; L K Borysiewicz
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

5.  Protection against feline leukemia virus infection by use of an inactivated virus vaccine.

Authors:  E A Hoover; N A Perigo; S L Quackenbush; C K Mathiason-DuBard; J M Overbaugh; W S Kloetzer; J H Elder; J I Mullins
Journal:  J Am Vet Med Assoc       Date:  1991-11-15       Impact factor: 1.936

6.  Experimental vaccine protection against feline immunodeficiency virus.

Authors:  J K Yamamoto; T Okuda; C D Ackley; H Louie; E Pembroke; H Zochlinski; R J Munn; M B Gardner
Journal:  AIDS Res Hum Retroviruses       Date:  1991-11       Impact factor: 2.205

7.  Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors.

Authors:  L Hanlon; D Argyle; D Bain; L Nicolson; S Dunham; M C Golder; M McDonald; C McGillivray; O Jarrett; J C Neil; D E Onions
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Reversal of feline leukemia virus infection by adoptive transfer of lectin/interleukin-2-activated lymphocytes, interferon-alpha, and zidovudine.

Authors:  N S Zeidner; C K Mathiason-DuBard; E A Hoover
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-07

9.  Induction of feline immunodeficiency virus-specific cytolytic T-cell responses from experimentally infected cats.

Authors:  W Song; E W Collisson; P M Billingsley; W C Brown
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

10.  Stimulation of a cell-mediated cytotoxic response to FeLV-induced T cell lymphomas in the cat.

Authors:  M B Tompkins; W A Tompkins
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

View more
  14 in total

1.  Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors.

Authors:  L Hanlon; D Argyle; D Bain; L Nicolson; S Dunham; M C Golder; M McDonald; C McGillivray; O Jarrett; J C Neil; D E Onions
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  Longitudinal analysis of feline leukemia virus-specific cytotoxic T lymphocytes: correlation with recovery from infection.

Authors:  J Norman Flynn; Stephen P Dunham; Vivien Watson; Oswald Jarrett
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Feline leukemia virus immunity induced by whole inactivated virus vaccination.

Authors:  Andrea N Torres; Kevin P O'Halloran; Laurie J Larson; Ronald D Schultz; Edward A Hoover
Journal:  Vet Immunol Immunopathol       Date:  2009-10-31       Impact factor: 2.046

4.  A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine.

Authors:  Géraldine Schlecht-Louf; Marianne Mangeney; Hanane El-Garch; Valérie Lacombe; Hervé Poulet; Thierry Heidmann
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

5.  Polymorphisms and tissue expression of the feline leukocyte antigen class I loci FLAI-E, FLAI-H, and FLAI-K.

Authors:  Jennifer C Holmes; Savannah G Holmer; Peter Ross; Adam S Buntzman; Jeffrey A Frelinger; Paul R Hess
Journal:  Immunogenetics       Date:  2013-06-30       Impact factor: 2.846

Review 6.  DNA vaccines in veterinary use.

Authors:  Laurel Redding; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2009-09       Impact factor: 5.217

7.  Broadening the use of antiretroviral therapy: the case for feline leukemia virus.

Authors:  Willie M Greggs; Christine L Clouser; Steven E Patterson; Louis M Mansky
Journal:  Ther Clin Risk Manag       Date:  2011-03-16       Impact factor: 2.423

8.  Exposure of cats to low doses of FeLV: seroconversion as the sole parameter of infection.

Authors:  Andrea Major; Valentino Cattori; Eva Boenzli; Barbara Riond; Peter Ossent; Marina Luisa Meli; Regina Hofmann-Lehmann; Hans Lutz
Journal:  Vet Res       Date:  2009-10-28       Impact factor: 3.683

9.  Difficulties in demonstrating long term immunity in FeLV vaccinated cats due to increasing age-related resistance to infection.

Authors:  Stephen Wilson; Juliet Greenslade; Gillian Saunders; Catherine Holcroft; Lynn Bruce; Andy Scobey; Tedd Childers; Gordon Sture; James Thompson
Journal:  BMC Vet Res       Date:  2012-07-28       Impact factor: 2.741

10.  Three-color flow cytometry detection of virus-specific CD4+ and CD8+ T cells in the cat.

Authors:  Jolanda D F de Groot-Mijnes; Robbert G van der Most; Jessica M van Dun; Eddie G te Lintelo; Nancy M P Schuurman; Herman F Egberink; Raoul J de Groot
Journal:  J Immunol Methods       Date:  2004-02-01       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.